Trial intelligence / Profile preview

AHB-137 in HBeAg-negative Chronic Hepatitis B

NCT07246889Phase 3Active, not recruiting

Sponsor
AusperBio
Start
Aug 2025
Primary completion
Dec 2026
Modality
Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
Countries
1
01

Overview

A Phase 3 trial of AHB-137 in Chronic Hepatitis B (CHB), sponsored by AusperBio. Started Aug 2025; status: active, not recruiting.

02

Drugs

AHB-137
03

Conditions

Chronic Hepatitis B (CHB)

Beyond the preview

Go deeper on NCT07246889.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07246889.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call